DNB Global Indeks A

Index fund

1 year

Region

USA

Largest region

Medium

Risk

Cost

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • DNB Global Indeks er et indeksnært aksjefond som hovedsakelig investerer i selskaper notert på børser og regulerte markeder i utviklede økonomier, definert ved fondets referanseindeks. Selskaper som ikke tilfredsstiller DNBs retningslinjer for ansvarlige investeringer vil holdes utenfor fondets investeringsområde. Målsetningen med fondet er over tid å gi avkastning tilnærmet lik referanseindeksen før kostnader. Fondet vil ha sammensetning og risiko omtrent som referanseindeksen.

Investment horizon

  • DNB Global Indeks A is a Index fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    04 Jun 2025

  • Start date
    23 Sept 2010
  • ISIN
    NO0010582984

Risk

  • Medium (4 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Costs

  • Ongoing costs

    Includes management fees of 0,10 %

  • Platform fee
  • Kickback fee
  • Annual running costs
  • Performance-based fee
  • Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.

Allocation

  • Stocks 100%
    Interest 0%

Portfolio

Shows the fund's largest investments.

  • Apple Inc
    4.7%
  • Microsoft Corp
    4.0%
  • NVIDIA Corp
    3.9%
  • Amazon.com Inc
    2.5%
  • Meta Platforms Inc Class A
    1.7%
  • Alphabet Inc Class A
    1.3%
  • Broadcom Inc
    1.2%
  • Tesla Inc
    1.2%
  • Alphabet Inc Class C
    1.2%
  • Eli Lilly and Co
    1.1%